|
Jul 23
|
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
|
|
Jun 30
|
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
|
|
Jun 25
|
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
|
|
Jun 25
|
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
|
|
Jun 23
|
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
|
|
Jul 25
|
Idorsia announces financial results for the first half 2024
|
|
Jun 21
|
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
|
|
Jun 3
|
New data with daridorexant to be presented at SLEEP 2024
|
|
May 31
|
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
|
|
May 10
|
Q1 2024 Viatris Inc Earnings Call
|
|
May 6
|
Bondholders approve amended terms of the 2024 convertible bonds
|
|
Jan 10
|
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
|
|
Dec 6
|
Idorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insiders
|
|
Jul 10
|
Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
|